alexa KLF4 Improve Prognosis of Triple-negative Breast Cancer by Suppression of Epithelial-mesenchymal Transition
ISSN: 2572-4118
Breast Cancer: Current Research
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business
  • Research Article   
  • Breast Can Curr Res, Vol 1(3): 110
  • DOI: 10.4172/2572-4118.1000110

KLF4 Improve Prognosis of Triple-negative Breast Cancer by Suppression of Epithelial-mesenchymal Transition

Takuya Nagata1*, Katsuo Shimada2, Lv Xiao Long1, Tomoyuki Okumura1, Kenichi Tazawa3, Koichi Higashiyama4, Tetsuro Shimzu5 and Takashi Ohnaga6
1Department of Surgery and Science, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, 2630 Sigitani Toyama 930-0194,, Japan
2Department of Surgery, Imizu Municipal Hospital, 20 Honoki Imizu Toyama 934-0053, Japan
3Department of Surgery, Itoigawa General Hospital, 457-1 Takegahana Itoigawa Niigata, 941-8502, Japan
4Department of Surgery, Asahi General Hospital, 477 Tomari Asahi Simoniikawa, 939-0798, Japan
5Department of Surgery, Saiseikai Toyama Hospital, 33-1, Kusunoki Toyama, 931-8533, Japan
6Central Research Laboratories, Toyama Industrial Technology Center, 150 Futagami-cho, Takaoka, Toyama 933-0981, Japan
*Corresponding Author: Takuya Nagata, Department of Surgery and Science, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan, Tel: +81-76-434-7331, Email: [email protected]

Received Date: Jun 18, 2016 / Accepted Date: Jul 14, 2016 / Published Date: Jul 28, 2016

Abstract

Background: The prognostic value of KLF4 in triple negative breast cancer (TNBC) was described. Here we report an analysis of KLF4 expression in peripheral blood circulating tumor cells (CTCs) from patients with TNBC, which provided evidence that KLF4 negatively regulates the metastasis and growth of TNBC.

Method: We assessed the expression levels of KLF4 in 84 patients with TNBC by immunohistochemical staining and studied the patterns of metastasis/recurrence clinicopathologically. In addition, CTCs in the peripheral blood of TNBC patients were identified and compared with primary lesions in terms of KLF4 expression. Moreover, the expression of KLF4 was inhibited by transfecting cultured TNBC cells (MDA-MB231) with the small interfering RNA (siRNA) of KLF4 to analyze the effects of KLF4 on cell proliferation and epithelial-mesenchymal transition (EMT) -like changes.

Results: In the 84 patients with TNBC, higher KLF4 expression was associated with significantly better overall survival (OS) and disease-free survival (DFS). An analysis of KLF4 expression in CTCs of the TNBC patients showed that KLF4 expression was lower in CTCs than in cancer cells in primary lesions. TNBC cells (MDA-MB231) with inhibited KLF4 expression exhibited a greater ability to growth than controls. These cells also underwent EMT-like changes with reduced expression of epitherial factors such as E-cadherin. Treating these TNBC cells with eribulin resulted a reduction of the expression of stem cell/EMT markers.

Conclusion: TNBC patients with reduced KLF4 expression had poor outcomes. The results of our experiments suggest the expression of KLF4 is one of the important factors that inhibit the EMT and growth of TNBC.

Keywords: Triple negative breast cancer; KLF4; Circulating tumor cell; Epithelial-mesenchymal transition; iPS cells-induced pluripotent stem cells; Antibody; Overall survival; Disease free survival; Small interfering RNA

Introduction

Triple negative breast cancer (TNBC) is consisted with heterogeneous groups that are known generally as the hormone receptor (HR) negative and ERBB2 receptor (HER2) negative intrinsic subtypes, and accounts for approximately 15% of all breast cancer cases [1]. Moreover, TNBC is known to be more sensitive to anticancer drugs than luminal type breast cancer. However, TNBC is highly malignant and prone to metastasis and relapse, and therefore has poorer prognosis than other sub-types [2]. The mechanism of higher malignancy of TNBC has not been sufficiently elucidated.

Currently, there are high expectations in regenerative medicine for using induced pluripotent stem (iPS) cells against difficult-to-treat diseases. iPS cells are prepared by introducing the genes Oct3/4 and Sox2 as well as other genes such as KLF4, c-Myc, Nanog, and Lin28 into normal human cells (e.g. fibroblasts) [3]. KLF4 is required for the epigenetic reprogramming of the somatic genome [4]. In contrast, it is reported that KLF4 is highly expressed in atypical epithelia, breast cancer, and squamous cell carcinoma of the laryngopharynx [5]. KLF4 and c-Myc are oncogenes that induce cell mutations. Mice engineered to highly express KLF4 develop skin hyperplasia and squamous cell carcinoma [6,7].

We have reported that breast cancer patients with strong expression of KLF4 had better prognosis, especially in TNBC patients [8,9]. In the present study, we analyzed KLF expression in TNBC patients that had the operation of breast cancer resection in our breast cancer research group hospitals. And we demonstrated that the inhibition of KLF4 expression up-regulated the activity of tumor growth and the expression of the epithelial to mesenchymal transition (EMT) markers in in vitro. These results revealed that the KLF4 plays an important role for reduction of tumor growth and metastasis in TNBC.

Patients and Methods

Patients

Consecutive 84 TNBC patients who underwent surgery at hospitals of toyama university breast research group (TUBRG) from January 2001 to December 2011 were evaluated. The study protocol was approved by the ethics committee in each hospital.

Immunohistochemical staining and analysis

Antibodies for the immunohistochemical staining were selected as follows. Anti-KLF4 (ab34814) was the IgG type rabbit polyclonal antibody. It was purchased from Abcam (Cambridge, UK). Slide glasses were incubated with the primary antibodies at an optimized titer and diluted using Universal blocking reagent (BioGenex, Fremont, CA, USA) for 60 min. The secondary antibodies used were goat antirabbit IgG-HRP according to the manufacturer’s instructions. Two pathologists analyzed the expression of each gene independently, and scored the intensity of expression as 0 (no expression), 1 (weak expression), 2 (moderate expression), or 3 (strong expression). They also scored the distribution of expression as 0 (none), 1 (1-50% of tumor cells), or 2 (50-100% of tumor cells).

On the basis of the total score, each patient was then classified into one of two groups, which were a low expression group (lower group: total score of 0-2) or a high expression group (higher/upper group: total score of 3-5).

Cell lines and culture conditions

We used human TNBC cell line MDA-MB-231 purchased from American Type Culture Collections (ATCC, Manassas, VA, USA). MDA-MB-231 was initially cultured in L15 medium (DS Pharma Biomedical, Tokyo, Japan) supplemented with 15% of heat-inactivated fetal bovine serum containing antibiotics (GIBCO, Grand Island, N.Y., USA). The cell culture was maintained in humidified incubators at 37°C in an atmosphere of 5% CO2 and 95% air.

Down regulation of KLF4 using small interfering RNA approach

Small interfering RNA (siRNA) against KLF4 or control was induced to the TNBC cell line by using the Silencer® select predesigned siRNA product (Life Technologies, Tokyo, Japan) respectively. MDA-MB-231 cells were transfected with 1 μM siRNA using the NeoFX Tranfection Kit (Life Technologies) in Opti-MEM I reduced serum medium (Life Technologies) at 37°C in an atmosphere of 5% CO2 for 48 hrs. The medium was removed and replaced with fresh culture medium supplemented with 10% fetal bovine serum. Control cells were similarly transfected with negative control siRNA. All experiments were performed at least three times.

Cell proliferation assay

For the proliferation assay, cell lines were grown in 96 well plates at a density of 1×104 cells per well. Measurements were made in triplicate for each of the cell lines by using MTT Assay Kit (Roche Diagnostics, Indianapolis, IN, USA). We evaluated 3 days after transfection.

CTC-detection by the polymeric CTC-chip

Production of the polymeric CTC-chip and antibody coating of the chip surface were carried out as described previously [10]. The microstructure of the chip consisted chiefly of an array of two different types of micro posts and the gap between microposts was enlarged to 200 μm in the area around the chip inlet.

Goat anti-mouse IgG antibody (Southern Biotech, Birmingham, AL) and mouse anti-human EpCAM antibody were used for chip coating. Three ml of TNBC patient’s blood sample was passed through the chip inlet, and detected cells were confirmed as CTCs by staining with modified Giemsa (differential quick stein kit; Funakoshi, Japan), anti CK18 mAb (Abcam plc, Cambridge, UK).

RNA extraction, cDNA synthesis and real-time PCR

Total RNA was extracted using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized using the PrimeScript First Strand cDNA synthesis kit (Takara Inc., Kyoto, Japan) and used for the quantitative polymerase chain reaction (qPCR) analysis. The cDNA samples were amplified in an Mx3000P real-time qPCR system (Agilent Technologies, Santa Clara, CA, USA) using SYBR Premix Ex Taq II (Takara Inc.), as described previously [11].

Each mRNA expression level was normalized to that of the reference gene GAPDH. The primer sequences are shown in Table 1. The expression level of each mRNA molecule was evaluated using the ΔΔCt method.

Gene   Size
product Forward and reverse primers (5'-3') (bp)
KLF4 F:ACCAGGCACTACCGTAAACACA 79
  R: GGTCCGACCTGGAAAATGCT  
Nanog F: ATGCCTCACACGGAGACTGT 83
  R: AAGTGGGTTGTTTGCCTTTG  
dck F:TCTCTGAATGGCAAGCTCAA 326
  R:CTATGCAGGAGCCAGCTTTC  
p63 F: CAGACTTGCCAGATCATCC 220
  R: CAGCATTGTCAGTTTCTTAGC  
p75 F: TGAGTGCTGCAAAGCCTGCAA 230
  R: TCTCATCCTGGTAGTAGCCGT  
Bmi-1 F: CCACCTGATGTGTGTGCTTTG 162
  R: TTCAGTAGTGGTCTGGTCTTGT  
CK13 F: TCCACACCAAGAGTGCAGAG 267
  R: TCTGGCACTCCATCTCACTG  
E-cadherin F: GTCTGTCATGGAAGGTGCT 370
  R: TACGACGTTAGCCTCGTTC  
N-cadherin F: AGCCAACCTTAACTGAGGAGT 136
  R: GGCAAGTTGATTGGAGGGATG  
Snail1 F: TCGGAAGCCTAACTACAGCGA 140
  R: AGATGAGCATTGGCAGCGAG  
Snail2 F:CGAACTGGACACACATACAGTG 87
  R:CTGAGGATCTCTGGTTGTGGT  
Vimentin F: AGTCCACTGAGTACCGGAGAC 98
  R: CATTTCACGCATCTGGCGTTC  
Zeb1 F: CAGCTTGATACCTGTGAATGGG 106
  R:TATCTGTGGTCGTGTGGGACT  
Zeb2 F: GGAAGACAAGCTTCATATTGC 330
  R:ATGGCTGTGTCACTGCGCTGA  
GAPDH F: ACCACAGTCCATGCCATCAC 452
  R: TCCACCACCCTGTTGCTGTA  

Table 1: Polymerase chain reaction primer sequences. F-Forward; RReverse.

Treatment with eribulin. Eribulin mesilate was chemically synthesised at Eisai Co., Ltd (Tsukuba, Japan). 1×106 of siKLF4 transfected cells were treated with 0.25 nM of eribulin for 24 hr followed by extracting the mRNA, as described before.

Statistical methods

The student’s t-test and chi-square test were used to compare clinicopathological data. The overall survival (OS) rate and the diseasefree survival (DFS) rate after surgery were calculated for each group by the Kaplan–Maier method, and differences were assessed by the logrank test. The Cox hazard regression model was used for multivariate analysis. AP value less than 0.05 were assumed to indicate significance. All analyses were done with JMP11.0 software.

Results

Expression of KLF4 and lymph node metastasis

KLF4 expression levels were evaluated in 84 TNBC patients. Out of the 84 cases examined, 27 (32%) showed high KLF4 expression (Upper) and 57 (68%) cases were low (Lower). No correlation between KLF4 expression and age, tumor diameter, T-factor, stage and Ki67 was proved, but more axial-lymph node metastasis was significantly shown in KLF4 lower group (Table 2).

  KLF4  
Character (n) Lower (57) Upper (27) p-value
Age (y.o) 57 59 0.587
diameter (cm) 2.95 2.08 0.245
T      
0/I 30 15 0.847
II/III/IV 27 12  
N      
0 36 24 0.047*
>1 21 3  
Stage      
0/I 24 15 0.742
II/III 33 12  
Ki67      
<14% 48 18 0.238
>14% 9 9  

Table 2: Expression of KLF4 in each characteristics. Upper and lower expression groups are defined in Sect. “Immunohistochemical staining and analysis”. p-value is represented by X2 analysis, * Value of p<0.05.

KLF4 and life period of TNBC patients

Overall survival (OS) and disease-free survival (DFS) in TNBC patients were compared between KLF4 upper and lower expression groups using the Kaplan-Mayer method (Figure 1). Results showed more favorable OS and DFS in the KLF4 upper expression group (OS, p=0.0118; DFS, p=0.0027).

breast-cancer-patients-upper-lower-groups

Figure 1: Survival rates of breast cancer patients with upper and lower groups of KLF4 expression. Right line, DFS; left line, OS. Pvalue with Log-rank test.

KLF4 expressions in CTCs from a TNBC patient

Usually, KLF4 was well expressed in nuclei and cytoplasm of TNBC cells in primary breast tumor. We captured some CTCs from the peripheral blood of a TNBC patient by the polymeric CTC-chip (Figure 2a). An analysis of KLF4 expression in CTCs of the TNBC patient showed that KLF4 expression was lower in CTCs than in cancer cells in primary lesions (Figure 2b). At the same time, the expression of the epitherial cell marker, E-cadherin was also weak in CTC than primary breast cancer cells.

breast-cancer-polymeric-CTC-chip

Figure 2: Detection of CTC cells, and comparison of the expression of KLF4 and E-cadherin. (a) Detected cells by polymeric CTC-chip were immunostained with anti-EpiCAM and anti-CK18 mAb. Double positive cell is confirmed as a CTC cell. (b) The specimen of resected breast tumor and CTCs in the peripheral blood of the same patient was immunostained with anti-KLF4 and anti-E-cadherin mAb.

Suppression of KLF4 in TNBC cells

To examine whether KLF4 may have a role in tumor growth and metastasis in TNBC cells, we induced the siRNA against human klf4 (siKLF4). Induction of siKLF4 upregulated the speed of cell growth and the cell volume in MDA-MB-231 cells (Figure 3a). The MTT assay also demonstrated that siKLF4 transfected MDA-MB-231 cells exhibited increased cell growth as compared to control cells (Figure 3b). Then, the qPCR assay was performed with the mRNA from these siKLF4 transfected MDA-MB-231 cells.

breast-cancer-Alteration-cell-growth-ability

Figure 3: Alteration of the cell growth ability in TNBC by inhibition of KLF4. (a) Micro scope images of siKLF4 transfected MDAMB- 231 cells (siKLF4) and control cells (control). (b) MTT assay demonstrated that siKLF4 transfected MDA-MB-231 cells exhibited the upregulation of cell viabillity as compared with the control cells (t test, *p<0.05).

The mRNA expression level of iPS inducing factor (KLF4), stem cell marker (Nanog and Bmi1), cell growth marker (dck), tumor growth suppression factor (p63), stress response factor (p75), epidermal cell marker (E-cadherin), and EMT-markers (N-cadherin, Snail1, Snail2, Vimentin, Zeb1, Zeb2) were elucidated.

The result showed the downregulation of KLF4, p63, p75 and Ecadherin, and the upregulation of NANOG, dck, Bmi1, CK13, Ncadherin, Snail1, Snail2, Vimentin, Zeb1 and Zeb2 (Figures 4a and 4b). Eribulin is reported to suppress the growth and EMT of breast cancer cells [12], and siKLF4 transfected MDA-MB-231 cells were treated with eriburlin to elucidate the KLF4 role for the growth and EMT of TNBC. The result showed the decrease of dck, Bmi1, CK13, and all of EMT-markers; N-cadherin, Snail1, Snail2, Vimentin, Zeb1 and Zeb2 significantly. On the other hand, p63, p75 and E-cadherin were increased. These results showed that the KLF4 had a tendency to inhibit the cell growth and the EMT of TNBC.

breast-cancer-siKLF4-transfected-TNBC

Figure 4: qPCR assay of siKLF4 transfected TNBC cells. The mRNA expression level of iPS inducing factor (KLF4), stem cell marker (Nanog and Bmi1), cell growth marker (dck), tumor growth suppression factor (p63), stress response factor (p75), epidermal cell marker (E-cadherin), and EMT-markers (N-cadherin, Snail1, Snail2, Vimentin, Zeb1, Zeb2) were shown. White bar: mRNA from siKLF4 transfected TNBC cells. Black bar: mRNA from Eribulin treated TNBC cells after the transfection of siKLF4 (t test, *p<0.05).

Discussion

In this report, we investigate the relationship between KLF4 and life expectancy in TNBC cases based on clinical data. Eighty-four TNBC cases were performed operations of breast cancers resection at 5 hospitals of TUBRG. All slide glasses of resected tumor specimen were immunostained with anti-KLF4 Ab. The result indicates that axillar lymph node metastasis is significantly increased in KLF4 lower group. It is also shown that OS and DFS are significantly lower in the KLF4 low expression group than in the KLF4 high expression group. These results suggest that the expression of KLF4 inhibit the lymph node metastasis and tumor progression of TNBC cells.

In order to confirm it, we detect CTCs in the peripheral blood of TNBC patient. It is reported that CD44hiCD24lo/- type breast cancer cells, which are supposed to be breast cancer stem cells (CSCs), are abundant in CTC of TNBC cases, resulting in metastasis and relapse at high frequencies [13]. It is believed that epithelial-mesenchymal transition (EMT) endows cancer cells with migratory and invasive properties, and induces cancer stem cell (CSC) properties [14]. The primary events of an EMT are the loss of epithelial markers, such as Ecadherin, followed by increased expression of mesenchymal markers, and rearrangement of the cytoskeleton. Consequently, CSCs have a lose polarity and develop a mesenchymal phenotype, acquire motility and metastatic capacity [15]. In this report, we detected CTCs by polymeric CTC-chip that we developed [16], and ascertained by modified Giemsa staining and immunostained with anti-EPICAM and anti-CK18 mAbs. After that, CTCs were immunostained with the anti- KLF4 mAb or the E-cadherin mAb which is the epitherial cell marker. The results show that both expression of KLF4 and E-cadherin are decreased in CTCs than cancer cells in primary tumors. From these data, it is suggested that there are some relationship between the disappearance of KLF4 and EMT causing CTC.

Deletion of KLf4 in breast cancer cells induces EMT-like morphological changes, and forced expression KLf4 promotes Ecadherin expression, thereby suppressing EMT-like changes [17]. Tiwari et al. reported that suppressing KLf4 in breast cancer cells induces Jnk1 (Mapk8)-mediated EMT [18]. It is also reported that cell invasion and migration ability were reinforced when siRNA against kLf4 (siKLF4) was transfected in TNBC cell line MDA-MB-231 [9]. In this report, the cell growth ability of siKLF4 transfected TNBC cells is upregulated, and the cell volume seems to be enlarged. mRNAs of cell growth marker such as dck, CSC marker; Nanog and Bmi1, and EMT markers; N-cadherin, Snail1, Snail2, Vimentin, Zeb1 and Zeb2, are increased respectively. P63 is known to be a member of p53 related metastasis suppressor gene family [19,20], and p75 is reported as a stress response protein that promotes cell survival in the presence of environmental stressors such as chemotherapy, radiation, heat, and serum starvation [21-24]. In siKLF4 transfected TNBC cells, p63 and p75 mRNAs are decreased, but after the anti-cancer agent; eribulin treatment, their expressions are obviously increased (Figures 4a and 4b). These results suggested that KLF4 might have ability to add a stress to cancer cells, inhibit the malignant transformation of TNBC, the conversion to CSCs by EMT and promotion of the metastasis and relapse of breast cancer.

Conclusion

The expression of KLF4 improves the outcome of TNBC patients by reducing the EMT, cell growth and metastasis. Increasing the expression of KLF4 may be a useful therapeutic strategy in inhibiting the metastasis and growth of TNBC.

Acknowledgements

We acknowledged to Dr. Kazuhiro Tsukada died at 5/ Mar/ 2016, for giving us a lot of helpful suggestions about this work. This work was partly supported by JSPS KAKENHI Grant Number 15K10181.

Conflict of Interest

All authors declare that there are no conflicts of interests.

References

Citation: Nagata T, Shimada K, Long XL, Okumura T, Tazawa K, et al. (2016) KLF4 Improve Prognosis of Triple-negative Breast Cancer by Suppression of Epithelial-mesenchymal Transition. Breast Can Curr Res 1: 110. Doi: 10.4172/2572-4118.1000110

Copyright: ©2016 Nagata T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Relevant Topics
Article Usage
  • Total views: 9361
  • [From(publication date): 9-2016 - Dec 07, 2019]
  • Breakdown by view type
  • HTML page views: 9260
  • PDF downloads: 101
Share This Article
Top